Finance

Lists
MANKIND:NSE
Mankind Pharma Ltd
₹2,455.00
+1.43%
(+34.70) 1D
Aug 7, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for MANKIND...
Open
₹2,430.00
High
₹2,456.00
Low
₹2,415.60
Mkt. cap
1.00T
Avg. vol.
420.03K
Volume
167.66K
P/E ratio
49.68
52-wk high
₹2,674.00
52-wk low
₹1,909.70
EPS
₹49.42
No. of employees
20K
Open
₹2,430.00
High
₹2,456.00
Low
₹2,415.60
Mkt. cap
1.00T
Avg. vol.
420.03K
Volume
167.66K
P/E ratio
49.68
52-wk high
₹2,674.00
52-wk low
₹1,909.70
EPS
₹49.42
No. of employees
20K
Profile
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
About Mankind Pharma Ltd
CEORajeev Juneja | Sheetal Arora
Employees20.5K
Founded1991
Headquarters-
SectorPharmaceutical industry
Websitemankindpharma.com
Last report
Jul 30, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
₹13.74 / ₹13.88
-1.01%miss
Revenue / Est. (INR)
40.31B / 39.60B
+1.78%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
36.97B
35.67B
34.43B
40.31B
Cost of goods sold
10.62B
9.78B
11.71B
10.98B
Cost of revenue
10.62B
9.78B
11.71B
10.98B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.25B
8.24B
15.80B
9.14B
Operating expense
19.35B
18.92B
14.77B
21.02B
Total operating expenses
29.98B
28.70B
26.48B
32.00B
Operating income
7.00B
6.97B
7.95B
8.30B
Other non operating income
918.70M
727.50M
-2.31B
450.00M
EBT including unusual items
6.24B
5.09B
6.59B
7.69B
EBT excluding unusual items
6.24B
6.16B
5.59B
7.69B
Income tax expense
1.04B
951.20M
997.50M
1.95B
Effective tax rate
16.64%
18.69%
15.13%
25.39%
Other operating expenses
8.88B
8.46B
-3.26B
9.63B
Net income
5.12B
4.09B
5.54B
5.68B
Net profit margin
13.84%
11.46%
16.10%
14.09%
Earnings per share
12.38
11.99
13.89
13.74
Interest and investment income
-
-
580.50M
-
Interest expense
-1.70B
-1.57B
-1.36B
-1.10B
Net interest expenses
-1.70B
-1.57B
-778.20M
-1.10B
Depreciation and amortization charges
2.22B
2.23B
2.23B
2.26B
EBITDA
9.20B
8.42B
9.97B
10.33B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps